{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:33Z","timestamp":1787243373327,"version":"build-2736575974"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norwegian Research Council","doi-asserted-by":"publisher","award":["328657"],"award-info":[{"award-number":["328657"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>In patients with gout there is a lack of longitudinal studies on the course of work productivity. We explored longitudinal changes in and predictors of work productivity over 2\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients in the NOR-Gout observational study with a recent gout flare and serum urate (sUA) &amp;gt;360\u2009\u00b5mol\/l attended tight-control visits during escalating urate lowering therapy according to a treat-to-target strategy. From the Work Productivity and Activity Impairment (WPAI) questionnaire, scores for work productivity and activity impairment were assessed over 2\u2009years together with the Beliefs about Medicines Questionnaire and a variety of demographic and clinical variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline patients had a mean age of 56.4\u2009years and 95% were males. WPAI scores at baseline were 5.0% work missed (absenteeism), 19.1% work impairment (presenteeism), 21.4% overall work impairment and 32.1% activity impairment. Work productivity and activity impairment improved during the first months, and remained stable at 1 and 2\u2009years. Comorbidities were not cross-sectionally associated with WPAI scores at baseline, but predicted worse work impairment and activity impairment at year 1. The Beliefs about Medicines Questionnaire subscale with concerns about medicines at baseline independently predicted worse overall work impairment and worse activity impairment at year 1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with gout who were intensively treated to the sUA target, work productivity and activity impairment were largely unchanged and at 1\u2009year predicted by comorbidities and patient concerns about medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead124","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T19:03:28Z","timestamp":1679339008000},"page":"3886-3892","source":"Crossref","is-referenced-by-count":4,"title":["Course and predictors of work productivity in gout \u2014 results from the NOR-Gout longitudinal 2-year treat-to-target study"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-9552","authenticated-orcid":false,"given":"Till","family":"Uhlig","sequence":"first","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars F","family":"Karoliussen","sequence":"additional","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Sexton","sequence":"additional","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-902X","authenticated-orcid":false,"given":"Sella Aarrestad","family":"Provan","sequence":"additional","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo, Norway"},{"name":"Section for Public Health, Inland Norway University of Applied Sciences , Hamar, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore K","family":"Kvien","sequence":"additional","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A","family":"Haavardsholm","sequence":"additional","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7317-8991","authenticated-orcid":false,"given":"Hilde Berner","family":"Hammer","sequence":"additional","affiliation":[{"name":"Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"2023120200580071500_kead124-B1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023120200580071500_kead124-B2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2023120200580071500_kead124-B3","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1136\/annrheumdis-2013-204647","article-title":"The global burden of gout: estimates from the Global Burden of Disease 2010 study","volume":"73","author":"Smith","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023120200580071500_kead124-B4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/03009742.2017.1405461","article-title":"Burden of gout in the Nordic region, 1990-2015: findings from the Global Burden of Disease Study 2015","volume":"47","author":"Kiadaliri","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"2023120200580071500_kead124-B5","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","article-title":"Gout","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Lancet"},{"key":"2023120200580071500_kead124-B6","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/rheumatology\/ket265","article-title":"Health-related quality of life in gout: a systematic review","volume":"52","author":"Chandratre","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2023120200580071500_kead124-B7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1477-7525-10-117","article-title":"Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey","volume":"10","author":"Khanna","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"2023120200580071500_kead124-B8","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/ar4281","article-title":"Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR)","volume":"15","author":"Scire","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2023120200580071500_kead124-B9","doi-asserted-by":"crossref","first-page":"i51","DOI":"10.1093\/rheumatology\/kex421","article-title":"Education and non-pharmacological approaches for gout","volume":"57","author":"Abhishek","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2023120200580071500_kead124-B10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023120200580071500_kead124-B11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/rheumatology\/kex150","article-title":"The British Society for Rheumatology guideline for the management of gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2023120200580071500_kead124-B12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13075-016-1062-6","article-title":"Incidence and prevalence of gout in Western Sweden","volume":"18","author":"Dehlin","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2023120200580071500_kead124-B13","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1001\/jama.2014.14484","article-title":"Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England","volume":"312","author":"Kuo","year":"2014","journal-title":"JAMA"},{"key":"2023120200580071500_kead124-B14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1524-4733.2007.00173.x","article-title":"The impact of gout on work absence and productivity","volume":"10","author":"Kleinman","year":"2007","journal-title":"Value Health"},{"key":"2023120200580071500_kead124-B15","doi-asserted-by":"crossref","first-page":"bjgpopen20X101003","DOI":"10.3399\/bjgpopen20X101003","article-title":"Understanding the patient voice in gout: a quantitative study conducted in Europe","volume":"4","author":"De Meulemeester","year":"2020","journal-title":"BJGP Open"},{"key":"2023120200580071500_kead124-B16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3899\/jrheum.140679","article-title":"Cost of illness and determinants of costs among patients with gout","volume":"42","author":"Spaetgens","year":"2015","journal-title":"J Rheumatol"},{"key":"2023120200580071500_kead124-B17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/1756-185X.13979","article-title":"Out-of-pocket spending among a cohort of Australians living with gout","volume":"24","author":"Nathan","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"2023120200580071500_kead124-B18","doi-asserted-by":"crossref","first-page":"e0261940","DOI":"10.1371\/journal.pone.0261940","article-title":"Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients","volume":"17","author":"van","year":"2022","journal-title":"PLoS ONE"},{"key":"2023120200580071500_kead124-B19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10198-014-0617-1","article-title":"Cost-effectiveness of febuxostat in chronic gout","volume":"15","author":"Beard","year":"2014","journal-title":"Eur J Health Econ"},{"key":"2023120200580071500_kead124-B20","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/rheumatology\/kev435","article-title":"Content validity of global measures for at-work productivity in patients with rheumatic diseases: an international qualitative study","volume":"55","author":"Leggett","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2023120200580071500_kead124-B21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"2023120200580071500_kead124-B22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1586\/erp.12.60","article-title":"The effect of gout on health-related quality of life, work productivity, resource use and clinical outcomes among patients with hypertension","volume":"12","author":"DiBonaventura","year":"2012","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2023120200580071500_kead124-B23","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40273-016-0441-9","article-title":"Nocturia work productivity and activity impairment compared with other common chronic diseases","volume":"34","author":"Miller","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"2023120200580071500_kead124-B24","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.3899\/jrheum.151199","article-title":"Patients with gout treated with conventional urate-lowering therapy: association with disease control, health-related quality of life, and work productivity","volume":"43","author":"Wood","year":"2016","journal-title":"J Rheumatol"},{"key":"2023120200580071500_kead124-B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13696998.2018.1532904","article-title":"The economic burden of uncontrolled gout: how controlling gout reduces cost","volume":"22","author":"Flores","year":"2019","journal-title":"J Med Econ"},{"key":"2023120200580071500_kead124-B26","doi-asserted-by":"crossref","first-page":"e001628","DOI":"10.1136\/rmdopen-2021-001628","article-title":"12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target","volume":"7","author":"Uhlig","year":"2021","journal-title":"RMD Open"},{"key":"2023120200580071500_kead124-B27","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023120200580071500_kead124-B28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2036.2004.02091.x","article-title":"The validity and accuracy of the Work Productivity and Activity Impairment questionnaire \u2013 irritable bowel syndrome version (WPAI: IBS)","volume":"20","author":"Reilly","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2023120200580071500_kead124-B29","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/art.10993","article-title":"The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research","volume":"49","author":"Sangha","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2023120200580071500_kead124-B30","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3899\/jrheum.110271","article-title":"Patient-reported outcomes in chronic gout: a report from OMERACT 10","volume":"38","author":"Singh","year":"2011","journal-title":"J Rheumatol"},{"key":"2023120200580071500_kead124-B31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2023120200580071500_kead124-B32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/00207411.1994.11449283","article-title":"The SF-36 Health Survey: development and use in mental health research and the IQOLA project","volume":"23","author":"Ware","year":"1995","journal-title":"Int J Ment Health"},{"key":"2023120200580071500_kead124-B33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/anr.1780320107","article-title":"Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis","volume":"32","author":"Lorig","year":"1989","journal-title":"Arthritis Rheum"},{"key":"2023120200580071500_kead124-B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08870449908407311","article-title":"The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication","volume":"14","author":"Horne","year":"1999","journal-title":"Psychol Health"},{"key":"2023120200580071500_kead124-B35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0022-3999(99)00057-4","article-title":"Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness","volume":"47","author":"Horne","year":"1999","journal-title":"J Psychosom Res"},{"key":"2023120200580071500_kead124-B36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/08039488.2019.1674376","article-title":"Reliability and validation of Swedish translation of Beliefs about Medication Specific (BMQ-Specific) and Brief Illness Perception Questionnaire (B-IPQ) for use in adolescents with attention-deficit hyperactivity disorder","volume":"74","author":"Emilsson","year":"2020","journal-title":"Nord J Psychiatry"},{"key":"2023120200580071500_kead124-B37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.pec.2014.05.010","article-title":"Lost in translation?: Comparing three Scandinavian translations of the Beliefs About Medicines questionnaire","volume":"96","author":"Granas","year":"2014","journal-title":"Patient Educ Counsel"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead124\/50607380\/kead124.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/12\/3886\/53972309\/kead124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/12\/3886\/53972309\/kead124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T19:58:36Z","timestamp":1701460716000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/12\/3886\/7082511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,3,21]]},"published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead124","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,1]]},"published":{"date-parts":[[2023,3,21]]}}}